Common asthma drug cuts COVID-19 hospitalization risk, recovery time - Oxford study

Common asthma drug cuts COVID-19 hospitalization risk, recovery time - Oxford study (reuters.com)

reuters.com

(Reuters) - A commonly used asthma treatment appears to reduce the need for hospitalizations as well as recovery time for COVID-19 patients if given within seven days of symptoms appearing, researchers at the University of Oxford said on Tuesday.

The findings were made following a mid-stage study of the steroid budesonide, sold as Pulmicort by AstraZeneca Plc and also used for treating smoker’s lung.

Read the complete article on reuters.com

Submitted by Admin on Tue, 02/09/2021 - 19:44